Citations

Clear

4847 citation(s) found for "Yu, Eric".

Long‐term oncologic outcomes in esthesioneuroblastoma: An institutional experience of 143 patients
McMillan, Ryan A. , Link, Michael J., Moore, Eric J. , Abel, Kathryn M. Van , O’Byrne, Jamie, Celda, María Peris, Foote, Robert L. , O'Byrne, Jamie, Chintakuntlawar, Ashish, Pinheiro Neto, Carlos D, Peris Celda, Maria, Van Abel, Kathryn M , McMillan, Ryan A , Gompel, Jamie J. Van , Price, Daniel L. , Giannini, Caterina , Chintakuntlawar, Ashish V. , Pinheiro‐Neto, Carlos , Choby, Garret

Mayo Clinic

International Forum of Allergy & Rhinology | April 6, 2022 | Volume: 12 | Issue: 12 | Pages: 1457-1467

10.1002/alr.23007 | PMID 35385606 Get It

AbstractObjectiveEsthesioneuroblastoma (ENB) is a rare malignant neoplasm arising from the olfactory epithelium of the cribriform plate. The goal of this study was to update our oncologic outcomes for this disease and explore prognostic factors associated with survival.Materials and methodsWe performed a retrospective analysis of patients with ENB treated at a single tertiary care institution from January 1, 1960, to January 1, 2020. Univariate and multivariate analysis was performed. Overall survival (OS), progression‐free survival (PFS), and distant metastasis–free survival (DMFS) were reported.ResultsAmong 143 included patients, the 5‐year OS was 82.3% and the 5‐year PFS was 51.6%; 5‐year OS and PFS have improved in the modern era (2005–present). Delayed regional nodal metastasis was the most common site of recurrence in 22% of patients (median, 57 months). On univariate analysis, modified Kadish staging (mKadish) had a negative effect on OS, PFS, and DMFS (p < 0.05). Higher Hyams grade had a negative effect on PFS and DMFS (p < 0.05). Positive margin status had a negative effect on PFS (p < 0.05). Orbital invasion demonstrated worsening OS (hazard ratio, 3.1; p < 0.05). On multivariable analysis, high Hyams grade (3 or 4), high mKadish stage (C+D), and increasing age were independent negative prognostic factors for OS (p < 0.05). High Hyams grade (3+4), high mKadish stage (C+D), age, and positive margin status were independent negative prognostic factors for PFS (p < 0.05). High Hyams grade (3+4) was an independent negative prognostic factor for DMFS (p < 0.05).ConclusionsPatients with low Hyams grade and mKadish stage have favorable 5‐year OS, PFS, and DMFS.
Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma
Prabhu, Sujit S. , Rao, Ganesh , Laxton, Adrian W. , Fecci, Peter E. , O’Brien, Barbara , Sloan, Andrew E. , Chiang, Veronica , Mohammadi, Alireza M. , Chen, Clark, Sun, David, Sinicrope, Kaylyn, Campian, Jian , Kurz, Sylvia C. , Smith, Kris A. , Tovar-Spinoza, Zulma , Leuthardt, Eric C. , Khasraw, Mustafa , Fecci, Peter E , Groot, John de , Kim, Albert H. , Tatter, Stephen B. , Placantonakis, Dimitris G. , Strowd, Roy E. , Hadjipanayis, Costas G. , Khasraw, Mustafa , Piccioni, David Eric , Williams, Brian J.

Mayo Clinic

Neuro-Oncology Advances | April 6, 2022 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdac040 | PMID 35611270 Get It

Abstract Background Treatment options for unresectable new and recurrent glioblastoma remain limited. Laser ablation has demonstrated safety as a surgical approach to treating primary brain tumors. The LAANTERN prospective multicenter registry (NCT02392078) data were analyzed to determine clinical outcomes for patients with new and recurrent IDH wild-type glioblastoma. Methods Demographics, intraprocedural data, adverse events, KPS, health economics, and survival data were prospectively collected and then analyzed on IDH wild-type newly diagnosed and recurrent glioblastoma patients who were treated with laser ablation at 14 US centers between January 2016 and May 2019. Data were monitored for accuracy. Statistical analysis included individual variable summaries, multivariable differences in survival, and median survival numbers. Results A total of 29 new and 60 recurrent IDH wild-type WHO grade 4 glioblastoma patients were treated. Positive MGMT promoter methylation status was present in 5/29 of new and 23/60 of recurrent patients. Median physician-estimated extent of ablation was 91%-99%. Median overall survival (OS) was 9.73 months (95% confidence interval: 5.16, 15.91) for newly diagnosed patients and median post-procedure survival was 8.97 months (6.94, 12.36) for recurrent patients. Median OS for newly diagnosed patients receiving post-LITT chemo/radiation was 16.14 months (6.11, not reached). Factors associated with improved survival were MGMT promoter methylation, adjuvant chemotherapy within 12 weeks, and tumor volume &lt;3 cc. Conclusions Laser ablation is a viable option for patients with new and recurrent glioblastoma. Median OS for IDH wild-type newly diagnosed glioblastoma is comparable to outcomes observed in other tumor resection studies when those patients undergo radiation and chemotherapy following LITT.
Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential
Nakao, Tetsushi , Bick, Alexander G. , Taub, Margaret A. , Uddin, Md Mesbah , Niroula, Abhishek , Carty, Cara L. , Lane, John , Honigberg, Michael C. , Weinstock, Joshua S. , Pampana, Akhil , Griffin, Gabriel K. , Bhattacharya, Romit , Assimes, Themistocles L. , Emery, Leslie S. , Wong, Quenna , Broome, Jai , Laurie, Cecelia , Khan, Alyna , Smith, Albert V. , Blackwell, Thomas W. , Nelson, Christopher P. , Yoneda, Zachary T. , Peralta, Juan M. , Bowden, Donald W. , Irvin, Marguerite R. , Boorgula, Meher Preethi, Zhao, Wei , Yanek, Lisa R. , Roden, Dan M. , Reupena, Muagututi‘a Sefuiva , DeMeo, Dawn L. , Kelly, Shannon , Musani, Solomon K., Bis, Joshua C. , Lloyd‐Jones, Donald M. , Peyser, Patricia A. , Qiao, Dandi , Tiwari, Hemant K., Smith, Jennifer A. , Smith, Nicholas L. , Kelly, Tanika N. , Hidalgo, Bertha , Weeks, Daniel E. , Group, The Samoan Obesity, Lifestyle and Genetic Adaptations Study (OLaGA), Deka, Ranjan , Naseri, Take, Fuentes, Lisa de las , Raffield, Laura M. , Morrison, Alanna C. , Vries, Paul S. de , Shoemaker, M. Benjamin , Palmer, Nicholette D. , Barnes, Kathleen C. , Redline, Susan , Kardia, Sharon L.R., Becker, Lewis C. , Heckbert, Susan R. , He, Jiang , Post, Wendy S. , Arnett, Donna K. , McGarvey, Stephen T. , Chen, Yii‐Der Ida , Kaplan, Robert C. , Meyers, Deborah A. , Fornage, Myriam , Boerwinkle, Eric , Loos, Ruth J. F. , Silverman, Edwin K. , Danesh, John , Samani, Nilesh J. , Jaiswal, Siddhartha , Ebert, Benjamin L. , Reiner, Alex P. , Mathias, Rasika A. , Do, Ron , Natarajan, Pradeep , Zhao, Wei , Zekavat, Seyedeh M , Uddin, Md M , Niroula, Abhishek , Lane, John , Honigberg, Michael C , Weinstock, Joshua S , Pampana, Akhil , Griffin, Gabriel K , Clarke, Shoa L , Bhattacharya, Romit , Assimes, Themistocles L , Emery, Leslie S , Stilp, Adrienne M , Wong, Quenna , Broome, Jai , Khan, Alyna T , Smith, Albert V , Codd, Veryan , Nelson, Christopher P , Yoneda, Zachary T , Peralta, Juan M , Yanek, Lisa R , Wiggins, Kerri L , Gu, C Charles , Peloso, Gina M , Roden, Dan M. , Hwu, Chii-Min , North, Kari E. , Bis, Joshua C , Lloyd-Jones, Donald M , Johnsen, Jill M , Preuss, Michael , Tracy, Russell P , Peyser, Patricia A , Qiao, Dandi , Curran, Joanne E , Freedman, Barry I , Chavan, Sameer , Smith, Jennifer A , Kelly, Tanika N , Hidalgo, Bertha , Weeks, Daniel E , Hawley, Nicola L , Minster, Ryan L , de las Fuentes, Lisa , Raffield, Laura M , Ballantyne, Christie M , Kenny, Eimear E , Rich, Stephen S , Whitsel, Eric A , Cho, Michael H , Palmer, Nicholette D , Mitchell, Braxton D , Shuldiner, Alan R , Redline, Susan , Heckbert, Susan R , He, Jiang , Post, Wendy , Arnett, Donna K , Vasan, Ramachandran S , Weiss, Scott T , McGarvey, Stephen T , Custer, Brian S , Correa, Adolfo , Manson, JoAnn E , Konkle, Barbara A , Loos, Ruth J F , Rotter, Jerome I , Silverman, Edwin K , Kooperberg, Charles , Samani, Nilesh J , Jaiswal, Siddhartha , Libby, Peter , Ellinor, Patrick T , Pankratz, Nathan , Ebert, Benjamin L , Mathias, Rasika A , Do, Ron , Natarajan, Pradeep , Morrison, Alanna C , Bick, Alexander G , Gibson, Christopher James , Clarke, Shoa L. , Codd, Veryan , Wiggins, Kerri L. , Hixson, James E. , Peloso, Gina M. , Tracy, Russell P. , Desai, Pinkal , Curran, Joanne E. , Freedman, Barry I. , Cupples, L. Adrienne , Group, The Samoan Obesity, Lifestyle and Genetic Adaptations Study (OLaGA), Naseri, Take K. , Ballantyne, Christie M. , Rich, Stephen S. , Cho, Michael H. , Pace, Betty S. , Blangero, John , Mitchell, Braxton D. , Shuldiner, Alan R. , Abecasis, Gonçalo R. , Vasan, Ramachandran S. , Darbar, Dawood , Weiss, Scott T. , Andrade, Mariza de , Custer, Brian , Psaty, Bruce M. , Manson, JoAnn E. , Konkle, Barbara A. , Rotter, Jerome I. , Kooperberg, Charles , Libby, Peter , Ellinor, Patrick T. , Pankratz, Nathan

Mayo Clinic

Science Advances | April 6, 2022 | Volume: 8 | Issue: 14 | Pages: No page available

10.1126/sciadv.abl6579 | PMID 35385311 Get It

Human genetic studies support an inverse causal relationship between leukocyte telomere length (LTL) and coronary artery disease (CAD), but directionally mixed effects for LTL and diverse malignancies. Clonal hematopoiesis of indeterminate potential (CHIP), characterized by expansion of hematopoietic cells bearing leukemogenic mutations, predisposes both hematologic malignancy and CAD. TERT (which encodes telomerase reverse transcriptase) is the most significantly associated germline locus for CHIP in genome-wide association studies. Here, we investigated the relationship between CHIP, LTL, and CAD in the Trans-Omics for Precision Medicine (TOPMed) program ( n = 63,302) and UK Biobank ( n = 47,080). Bidirectional Mendelian randomization studies were consistent with longer genetically imputed LTL increasing propensity to develop CHIP, but CHIP then, in turn, hastens to shorten measured LTL (mLTL). We also demonstrated evidence of modest mediation between CHIP and CAD by mLTL. Our data promote an understanding of potential causal relationships across CHIP and LTL toward prevention of CAD.
National trends in prescription drug expenditures and projections for 2022
Tichy, Eric M. , Hoffman, James M. , Suda, Katie J. , Rim, Matthew H, Tadrous, Mina , Cuéllar, Sandra , Clark, John Spencer , Ward, Jennifer , Schumock, Glen T., Ward, Jennifer

Mayo Clinic

American Journal of Health-System Pharmacy | April 6, 2022 | Volume: 79 | Issue: 14 | Pages: 1158-1172

10.1093/ajhp/zxac102 | PMID 35385103 Get It

Abstract Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2022 in the United States, with a focus on the nonfederal hospital and clinic sectors. Methods Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2022 were reviewed—including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for biosimilars, cancer drugs, generics, COVID-19 pandemic influence, and specialty drugs. For nonfederal hospitals, clinics, and overall (all sectors), estimates of growth of pharmaceutical expenditures in 2022 were based on a combination of quantitative analyses and expert opinion. Results In 2021, overall pharmaceutical expenditures in the US grew 7.7% compared to 2020, for a total of $576.9 billion. Utilization (a 4.8% increase), price (a 1.9% increase) and new drugs (a 1.1% increase) drove this increase. Adalimumab was the top drug in terms of overall expenditures in 2021, followed by apixaban and dulaglutide. Drug expenditures were $39.6 billion (a 8.4% increase) and $105.0 billion (a 7.7% increase) in nonfederal hospitals and in clinics, respectively. In clinics and hospitals, new products and increased utilization growth drove growth, with decreasing prices for both sectors acting as an expense restraint. Several new drugs that are likely to influence spending are expected to be approved in 2022. Specialty and cancer drugs will continue to drive expenditures along with the evolution of the COVID-19 pandemic. Conclusion For 2022, we expect overall prescription drug spending to rise by 4.0% to 6.0%, whereas in clinics and hospitals we anticipate increases of 7.0% to 9.0% and 3.0% to 5.0%, respectively, compared to 2021. These national estimates of future pharmaceutical expenditure growth may not be representative of any particular health system because of the myriad of local factors that influence actual spending.
Rheumatoid interstitial lung disease in Canterbury New Zealand: prevalence, risk factors and long-term outcomes—protocol for a population-based retrospective study
Farquhar, Hamish , Edwards, Adrienne L. , Matteson, Eric L. , Thiessen, Rennae, Ganly, Edward, Beckert, Lutz , Stamp, Lisa K.

Mayo Clinic

BMJ Open | April 5, 2022 | Volume: 12 | Issue: 4 | Pages: e050934

10.1136/bmjopen-2021-050934 | PMID 35383056 Get It

Introduction Rheumatoid arthritis (RA) affects approximately 0.5%–1% of the general population. Clinically significant interstitial lung diseases (ILD) develops in just under 10% of people with RA, and subclinical disease is more common. Little is known about RA-ILD in New Zealand (NZ), or the number of persons with RA in Canterbury, NZ. This study aims to determine: (1) incidence and prevalence of RA, (2) incidence and prevalence of RA-ILD, (3) clinical characteristics and risk factors for the development of RA-ILD, (4) long-term outcomes of RA-ILD, in the population resident within the Canterbury District Health Board (CDHB) catchment area. Methods and analysis Persons aged 18 years of age and older, and resident in the region covered by the CDHB with RA as well as RA-ILD will be identified by retrospective review of medical records. Prevalent as well as incident cases of RA between 1 January 2006 and 31 December 2008 and between 1 January 2011 and 31 December 2013 will be identified, and followed until 30 June 2019. Existing as well as incident cases of RA-ILD during this time will be identified. The association between the development of ILD and clinical characteristics and environmental exposures will be examined using Cox-proportional hazard models. Kaplan-Meier methods will be used to estimate survival rates for patients with RA-ILD. Mortality for people with RA and RA-ILD will also be compared with the general population of the CDHB. Ethics and dissemination Data will be obtained by retrospective review of medical records. Deidentified patient data will be stored in a secure online database. Data on individual patients will not be released, and all results will only be published in aggregate. Ethical approval has been obtained from the University of Otago Human Research Ethics Committee (REF HD18/079). Results will be published in peer-reviewed medical journals and presented at conferences. Trial registration number ACTRN12619001310156; Pre-results.
European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing
Wilde, Arthur A.M. , Semsarian, Christopher, Shamloo, Alireza Sepehri , Ackerman, Michael J. , Ashley, Euan A. , Eduardo, Back Sternick, Barajas-Martínez, Héctor , Behr, Elijah R. , Breckpot, Jeroen , Chockalingam, Priya , Crotti, Lia , Lubitz, Steven A. , Makita, Naomasa , Ohno, Seiko, Ortiz‐Genga, Martín, Sacilotto, Luciana , Schulze‐Bahr, Eric , Sotoodehnia, Nona , Tadros, Rafik, Ware, James S. , Kaufman, Elizabeth S. , Aiba, Takeshi , Bollmann, Andreas, Choi, Jong‐Il , Dalal, Aarti , Darrieux, Francisco , Giudicessi, John, Guerchicoff, Mariana , Intyre, Ciorsti Mac, Mackall, Judith A. , Napolitano, Carlo , Juan, Pablo Ochoa, Peichl, Petr , Pereira, Alexandre C. , Skinner, Jon, Tfelt‐Hansen, Jacob , Deneke, Thomas, Mac Intyre, Ciorsti, Crotti, Lia , Makita, Naomasa , Behr, Elijah Raphael , Tfelt-Hansen, Jacob , Lubitz, Steven A , Peichl, Petr , Ware, James S , Márquez, Manlio F. , Bezzina, Connie R. , Charron, Philippe , Gollob, Michael H. , Ohno, Seiko , Shimizu, Wataru , Winlaw, David Scott , Aiba, Takeshi , Giudicessi, John R. , Hong, Kui , Krahn, Andrew D. , Mont, Lluís , Schwartz, Peter J. , Stellbrink, Christoph , Deneke, Thomas

Mayo Clinic

Journal of Arrhythmia | April 4, 2022 | Volume: 38 | Issue: 4 | Pages: 491-553

10.1002/joa3.12717 | PMID 35936045 Get It

European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases
Wilde, Arthur A.M. , Semsarian, Christopher, Shamloo, Alireza Sepehri , Ackerman, Michael J. , Ashley, Euan A. , Barajas-Martinez, Héctor, Behr, Elijah R. , Breckpot, Jeroen , Chockalingam, Priya, Crotti, Lia , Lubitz, Steven A. , Makita, Naomasa , Ohno, Seiko , Ortiz‐Genga, Martín, Sacilotto, Luciana, Schulze‐Bahr, Eric , Sotoodehnia, Nona , Ware, James S. , Kaufman, Elizabeth S. , Reviewers, Document, Aiba, Takeshi , Bollmann, Andreas, Choi, Jong‐Il , Dalal, Aarti , Darrieux, Francisco , Giudicessi, John, Guerchicoff, Mariana , MacIntyre, Ciorsti, Mackall, Judith A. , Napolitano, Carlo , Ochoa, Juan Pablo , Peichl, Petr , Pereira, Alexandre C., Skinner, Jon, Tfelt‐Hansen, Jacob , Deneke, Thomas, Crotti, Lia , Sacilotto, Luciana , Chockalingam, Priya , Crotti, Lia , Makita, Naomasa , Behr, Elijah Raphael , Tfelt-Hansen, Jacob , Lubitz, Steven A , Peichl, Petr , Ware, James S , Márquez, Manlio F. , Sternick, Eduardo Back , Bezzina, Connie R. , Charron, Philippe , Gollob, Michael H. , Ohno, Seiko , Shimizu, Wataru , Tadros, Rafik , Winlaw, David Scott , Reviewers, Document, Aiba, Takeshi , Giudicessi, John R. , Hong, Kui , Krahn, Andrew D. , Mont, Lluís , Schwartz, Peter J. , Stellbrink, Christoph , Deneke, Thomas

Mayo Clinic

Europace | April 4, 2022 | Volume: 24 | Issue: 8 | Pages: 1307-1367

10.1093/europace/euac030 | PMID 35373836 Get It

International consensus statement on allergy and rhinology: Olfaction
Patel, Zara M. , Holbrook, Eric H. , Turner, Justin H. , Adappa, Nithin D. , Albers, Mark W. , Altundağ, Aytuğ , Appenzeller, Simone , Costanzo, Richard M. , Croy, Ilona , Davis, Greg E. , Dehgani‐Mobaraki, Puya , Doty, Richard L. , Haehner, Antje , Hopkins, Claire , Hummel, Thomas , Jitaroon, Kawinyarat, Kern, Robert C. , Khanwalkar, Ashoke , Kobayashi, Masayoshi , Leopold, Donald A., Levy, Joshua M. , Marmura, Michael J. , Mclelland, Lisha, Miwa, Takaki , Moberg, Paul J., Mueller, Christian A. , Nigwekar, Sagar U. , O’Brien, Erin K. , Păunescu, Teodor G. , Philpott, Carl , Pinto, Jayant M. , Reiter, Evan R. , Schlosser, Rodney J. , Schwob, James E. , Seiden, Allen M., Smith, Timothy L. , Sowerby, Leigh J. , Tan, Bruce K. , Thamboo, Andrew , Wrobel, Bozena , Yan, Carol H. , Duffy, Valerie B , Goldstein, Bradley J , Gudis, David A , Haehner, Antje , Higgins, Thomas S , Hopkins, Claire , Huart, Caroline , Hummel, Thomas , Kern, Robert C , Khanwalkar, Ashoke R , Kobayashi, Masayoshi , Kondo, Kenji , Lane, Andrew P , Levy, Joshua M , Marmura, Michael J , O'Brien, Erin K , Paunescu, Teodor G , Pellegrino, Robert , Philpott, Carl , Roalf, David R , Rowan, Nicholas R , Schlosser, Rodney J , Schwob, James , Smith, Timothy L , Sowerby, Leigh , Yan, Carol , Holbrook, Eric H , Patel, Zara , Albers, Mark W , Adappa, Nithin D. , Gudis, David A. , Lechner, Matt , Rowan, Nicholas R. , Soler, Zachary M.

Mayo Clinic

International Forum of Allergy & Rhinology | April 3, 2022 | Volume: 12 | Issue: 4 | Pages: 327-680

10.1002/alr.22929 | PMID 35373533 Get It

Abstract Background The literature regarding clinical olfaction, olfactory loss, and olfactory dysfunction has expanded rapidly over the past two decades, with an exponential rise in the past year. There is substantial variability in the quality of this literature and a need to consolidate and critically review the evidence. It is with that aim that we have gathered experts from around the world to produce this International Consensus on Allergy and Rhinology: Olfaction (ICAR:O). Methods Using previously described methodology, specific topics were developed relating to olfaction. Each topic was assigned a literature review, evidence‐based review, or evidence‐based review with recommendations format as dictated by available evidence and scope within the ICAR:O document. Following iterative reviews of each topic, the ICAR:O document was integrated and reviewed by all authors for final consensus. Results The ICAR:O document reviews nearly 100 separate topics within the realm of olfaction, including diagnosis, epidemiology, disease burden, diagnosis, testing, etiology, treatment, and associated pathologies. Conclusion This critical review of the existing clinical olfaction literature provides much needed insight and clarity into the evaluation, diagnosis, and treatment of patients with olfactory dysfunction, while also clearly delineating gaps in our knowledge and evidence base that we should investigate further.
Feasibility of Instituting a Clinical Otolaryngology Human Papillomavirus (HPV) Vaccination Program
Palacios, Victoria J. , Merlino, Dante J. , Anderson, Stephanie S., Yeakel, Sarah R., Wiedermann, Joshua P. , Moore, Eric J. , O’Byrne, Thomas J., Abel, Kathryn M. Van , Choby, Garret , Moore, Eric J , O'Byrne, Thomas J, Jacobson, Robert M. , Van Abel, Kathryn M , Yeakel, Sarah, Choby, Garret

Mayo Clinic

The Laryngoscope | April 2, 2022 | Volume: 133 | Issue: 1 | Pages: 116-123

10.1002/lary.30130 | PMID 35366006 Get It

ObjectivesTo measure baseline human papillomavirus (HPV) vaccination rates among tertiary and community‐based Otolaryngology – Head and Neck Surgery (Oto‐HNS) clinic patients and to determine risk factors for under‐vaccination.MethodsRetrospective chart review of patients aged 9 to 26 years presenting to an Oto‐HNS clinic from 2017 to 2019. Patients were considered complete for HPV vaccination if they received two doses of HPV vaccine with the first dose received before age 15 years or three doses of HPV vaccine otherwise.Results8,532 unique patients met the criteria. At the index visit, 3,110 (36.5%) had completed the HPV series, 5,422 (63.5%) were due for one or more doses, with 4,981 (58.4%) eligible for vaccination at the time of their appointment. Of those dues, most (3,148/5,422 or 58%) were past due by age (≥13 years old). Of the 3,148 patients past due, 745 (23.7%) were partially vaccinated and 2,403 (76.3%) were vaccine naïve. Male sex and younger age were both independently associated with incomplete vaccination (p < 0.0001).ConclusionThis study demonstrates that the implementation of on‐site HPV vaccination has the potential to increase the opportunities for vaccination among vaccine‐eligible patients, especially among young males. Otolaryngologists have the potential to provide meaningful preventive services in the fight against HPV‐mediated disease.Level of Evidence3 Laryngoscope, 133:116–123, 2023